Location History:
- Tokyo, JP (2015)
- Shinagawa-ku, JP (2020)
- Koto-ku, JP (2022)
Company Filing History:
3 out of 441 
1 out of 222 
Years Active: 2015-2022
Title: Saito Higuchi: Innovator in Cancer Treatment
Introduction
Saito Higuchi is a notable inventor based in Koto-ku, Japan, recognized for his contributions to cancer treatment through innovative compounds. With a total of three patents to his name, Higuchi has made significant strides in the field of pharmacology.
Latest Patents
Higuchi's latest patents include an EP300/CREBBP inhibitor, which provides a compound exhibiting excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP. This compound is represented by a specific formula or a pharmacologically acceptable salt thereof. Another significant patent is a method for predicting responsiveness to cancer treatment using a p300-inhibiting compound. This method reveals that CBP and p300 are in a relationship of synthetic lethality, making p300 inhibition a promising approach for treating CBP-mutated cancer. The therapeutic strategy allows for efficient treatment based on companion diagnostics, as a p300 inhibitor can be administered to cancer patients selected with functional suppression of CBP as an index.
Career Highlights
Throughout his career, Saito Higuchi has worked with prominent organizations, including Daiichi Sankyo Company, Limited and the National Cancer Center. His work has focused on developing innovative solutions for cancer treatment, showcasing his commitment to advancing medical science.
Collaborations
Higuchi has collaborated with notable colleagues, including Hiroyuki Naito and Yoshiko Kagoshima, who have contributed to his research endeavors.
Conclusion
Saito Higuchi's innovative work in cancer treatment through his patents highlights his significant impact on the field of pharmacology. His contributions continue to pave the way for advancements in therapeutic strategies against cancer.